Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
NCT06534125

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

Led by Emory University · Updated on 2026-01-29

150

Participants Needed

4

Research Sites

159 weeks

Total Duration

On this page

Sponsors

E

Emory University

Lead Sponsor

B

Bristol-Myers Squibb

Collaborating Sponsor

AI-Summary

What this Trial Is About

This clinical trial evaluates if in-person acupuncture or virtual acupressure therapy prevents aromatase inhibitor-associated joint pain in Non-Hispanic Black postmenopausal women with stage I-III (early-stage) hormone receptor positive (HR+) breast cancer. Aromatase inhibitors (AI) are medications that prevent the formation of the hormone estrogen. They are used in the treatment of postmenopausal women who have hormone-dependent breast cancer. AI therapy prolongs life among patients with early-stage HR+ breast cancer. Many postmenopausal women stop AI therapy early due to debilitating joint pain (arthralgias). Non-Hispanic Black women are more likely to experience side effects and stop their hormonal therapy compared to Non-Hispanic white women. Acupuncture therapy involves inserting thin needles through the skin at specific points on the body to control pain. Acupressure therapy uses the application of pressure or localized massage to specific sites on the body to control symptoms such as pain. Acupuncture and acupressure are types of complementary and alternative medicine. Undergoing in-person acupuncture or participating in virtual acupressure may prevent AI-associated arthralgias (AIAA) in Non-Hispanic Black postmenopausal women with early-stage HR+ breast cancer.

CONDITIONS

Official Title

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Self-identified as Non-Hispanic Black woman
  • Postmenopausal status (at least 12 months since last menstrual period, or history of bilateral salpingo-oophorectomy, or hormone levels consistent with menopause)
  • Diagnosed with stage I-III hormone receptor-positive and HER2-negative breast cancer
  • Completed all active cancer treatments (surgery, chemotherapy, radiation) at least 14 days before enrollment
  • Planned to start adjuvant aromatase inhibitor therapy
Not Eligible

You will not qualify if you...

  • Diagnosed with metastatic breast cancer
  • Premenopausal status
  • History of allergic reactions to acupuncture needles or similar compounds
  • Diagnosis of rheumatoid arthritis, multiple sclerosis, or muscular dystrophy
  • Current or past use of CDK 4/6 inhibitors
  • History of neoadjuvant aromatase inhibitor use
  • Use of adjuvant aromatase inhibitors for more than 14 days
  • Received acupuncture within 60 days prior to study start

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Grady Health System

Atlanta, Georgia, United States, 30303

Actively Recruiting

2

Emory University Hospital Midtown

Atlanta, Georgia, United States, 30308

Actively Recruiting

3

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States, 30322

Actively Recruiting

4

Emory Saint Joseph's Hospital

Atlanta, Georgia, United States, 30342

Actively Recruiting

Loading map...

Research Team

D

Demetria Smith-Graziani, MD, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here